The agency said it was not yet ready to authorize Emergent BioSolutions Inc’s plant for manufacturing the J&J vaccine. One source familiar with the matter told Reuters that the J&J doses are expected to be exported to other countries. Safety concerns about the J&J vaccine paired with flagging U.S. demand for vaccinations in general have slowed rollout of the one-shot vaccine to a crawl. The FDA said its decision allows for the J&J doses to be used in the United States or exported. ADVERTISEMENTThe April halt followed the discovery that ingredients from AstraZeneca’s COVID-19 vaccine, also being produced at the plant at the time, contaminated a batch of J&J’s vaccine.

Source: Philippine Daily Inquirer June 11, 2021 21:26 UTC